Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Leukosight

Leukosight
2006 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
2ndary - Private LATEST DEAL TYPE
5 INVESTORS
Description

Provider of anti-inflammatory therapeutics. The company offers therapeutics that can be used to treat auto-immune and inflammatory diseases.

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 1107 Microbiology Building
  • 231 B Campus Drive
  • College Park, MD
  • United States

+1 (301) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Leukosight’s full profile, request a free trial.

Leukosight Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private Completed Generating Revenue
4. Grant 30-Apr-2014 00000 Completed Startup
3. Grant 10-Jul-2012 00000 Completed Startup
2. Early Stage VC Completed Startup
1. Grant 01-May-2009 $150K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Leukosight Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
Maryland Biotechnology Center Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
Maryland Small Business Development Center Accelerator/Incubator 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0

Leukosight Executive Team (2)

Name Title Board
Seat
Contact
Info
David Mosser Ph.D Chief Executive Officer
Xia Zhang President

Leukosight Board Members (3)

Name Representing Role Since Contact
Info
Gary Noel Leukosight Board Member 000 0000
Steven Burke MD Self Board Member 000 0000

1 Former Board Member

You’re viewing 2 of 3 board members. Get the full list »